Irma Zhang1, Ana Barac2,3,4. 1. Georgetown University School of Medicine, Washington, DC, USA. 2. Georgetown University School of Medicine, Washington, DC, USA. Ana.Barac@medstar.net. 3. Medstar Washington Hospital Center, 110 Irving Street, NW, Ste 1A130, Washington, DC, 20010, USA. Ana.Barac@medstar.net. 4. National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Ana.Barac@medstar.net.
Abstract
PURPOSE OF REVIEW: This review summarizes current HER2-targeted therapies and clinical studies that have investigated primary and secondary prevention of cardiac dysfunction for HER2 + breast cancer patients undergoing targeted therapy. RECENT FINDINGS: Primary and secondary prevention clinical trials highlight the importance of cardioprotective measures during HER2 + cancer treatment. Together, these studies suggest the safety of neurohormonal drugs, the importance for an individualized approach in starting cardiopreventive therapies, and the potential to expand HER2 + treatment options to patients with cardiac dysfunction. Cardiac dysfunction is a concerning adverse effect for HER2-targeted treatment. The goal of primary and secondary prevention is to prevent (further) cardiac function decline and heart failure symptoms, while delivering appropriate cancer therapy. Clinical trials investigating preventative therapies in the context of primary and secondary prevention are paving the path for reducing adverse cardiac effects and expanding treatment options for patients previously unable to undergo HER + therapy.
PURPOSE OF REVIEW: This review summarizes current HER2-targeted therapies and clinical studies that have investigated primary and secondary prevention of cardiac dysfunction for HER2 + breast cancer patients undergoing targeted therapy. RECENT FINDINGS: Primary and secondary prevention clinical trials highlight the importance of cardioprotective measures during HER2 + cancer treatment. Together, these studies suggest the safety of neurohormonal drugs, the importance for an individualized approach in starting cardiopreventive therapies, and the potential to expand HER2 + treatment options to patients with cardiac dysfunction. Cardiac dysfunction is a concerning adverse effect for HER2-targeted treatment. The goal of primary and secondary prevention is to prevent (further) cardiac function decline and heart failure symptoms, while delivering appropriate cancer therapy. Clinical trials investigating preventative therapies in the context of primary and secondary prevention are paving the path for reducing adverse cardiac effects and expanding treatment options for patients previously unable to undergo HER + therapy.
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Patricia A Ganz; Edward H Romond; Reena S Cecchini; Priya Rastogi; Charles E Geyer; Sandra M Swain; Jong-Hyeon Jeong; Louis Fehrenbacher; Howard M Gross; Adam M Brufsky; Patrick J Flynn; Tanya A Wahl; Thomas E Seay; James L Wade; David D Biggs; James N Atkins; Jonathan Polikoff; John L Zapas; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544
Authors: Susan F Dent; Robin Kikuchi; Lavanya Kondapalli; Roohi Ismail-Khan; Christine Brezden-Masley; Ana Barac; Michael Fradley Journal: Am Soc Clin Oncol Educ Book Date: 2020-03
Authors: Diogo Mendes; Carlos Alves; Noémia Afonso; Fátima Cardoso; José Luís Passos-Coelho; Luís Costa; Sofia Andrade; Francisco Batel-Marques Journal: Breast Cancer Res Date: 2015-11-17 Impact factor: 6.466